Infectious Disease Diagnostics Market

Executive Summary

Infectious Disease Diagnostics Market was valued at US $41.41 billion in 2021 and is projected to grow at 3.52% CAGR over the forecast period to reach US $50.97 billion by 2027. Infectious Disease Diagnostics Market represented US $2.77 billion opportunity over 2019-2021 and estimated to create US $9.56 billion opportunity in 2027 over 2021.

Infectious Disease Diagnostics from Consainsights analyses the Infectious Disease Diagnostics Market in the Life Sciences industry over the forecast period to 2027.

Infectious Disease Diagnostics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Infectious Disease Diagnostics segmentation includes Product & Service, Technology, Disease Type, End User and Geography.

Based on the Product & Service, the Infectious Disease Diagnostics analysis covers Assays, Kits, & Reagents, Instruments, Services & Software.

In Product & Service segment, Assays, Kits, & Reagents segment has highest cagr growth of 3.12%.

Based on the Technology, the Infectious Disease Diagnostics analysis covers Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing & Next-Generation Sequencing (NGS), DNA Microarray, Other Technologies.

In Technology segment, Immunodiagnostics segment has highest cagr growth of 3.12%.

Based on the Disease Type, the Infectious Disease Diagnostics analysis covers Hepatitis, Human Immunodeficiency Virus (HIV), Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG), Hospital-Acquired Infections (HAIS), Human Papillomavirus (HPV), Tuberculosis (TB), Influenza, Other Infectious Diseases.

In Disease Type segment, Hepatitis segment has highest cagr growth of 3.12%.

Based on the End User, the Infectious Disease Diagnostics analysis covers Hospital/Clinical Laboratories, Reference Laboratories, Physician Offices, Academic/Research Institutes, Other End Users.

In End User segment, Hospital/Clinical Laboratories segment has highest cagr growth of 3.12%.

Based on the region, the Infectious Disease Diagnostics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Abbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product & Service

Introduction

In 2021, Assays, Kits, & Reagents segment has the highest revenue of US $21.61 billion and is expected to grow at CAGR of 3.12% by 2027 Assays, Kits, & Reagents segment has highest cagr growth of 3.12%.

Assays, Kits, & Reagents

Assays, Kits, & Reagents segment was valued at US $20.16 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $26.60 billion by 2027. Assays, Kits, & Reagents segment represented US $1.45 billion opportunity over 2019-2021 and estimated to create US $4.99 billion opportunity in 2027 over 2021.

Instruments

Instruments segment was valued at US $7.89 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $10.40 billion by 2027. Instruments segment represented US $0.57 billion opportunity over 2019-2021 and estimated to create US $1.95 billion opportunity in 2027 over 2021.

Services & Software

Services & Software segment was valued at US $10.59 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $13.97 billion by 2027. Services & Software segment represented US $0.76 billion opportunity over 2019-2021 and estimated to create US $2.62 billion opportunity in 2027 over 2021.

Technology

Introduction

In 2021, Immunodiagnostics segment has the highest revenue of US $16.59 billion and is expected to grow at CAGR of 3.12% by 2027 Immunodiagnostics segment has highest cagr growth of 3.12%.

Immunodiagnostics

Immunodiagnostics segment was valued at US $15.48 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $20.42 billion by 2027. Immunodiagnostics segment represented US $1.11 billion opportunity over 2019-2021 and estimated to create US $3.83 billion opportunity in 2027 over 2021.

Clinical Microbiology

Clinical Microbiology segment was valued at US $9.38 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $12.37 billion by 2027. Clinical Microbiology segment represented US $0.67 billion opportunity over 2019-2021 and estimated to create US $2.32 billion opportunity in 2027 over 2021.

Polymerase Chain Reaction (PCR)

Polymerase Chain Reaction (PCR) segment was valued at US $5.43 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $7.16 billion by 2027. Polymerase Chain Reaction (PCR) segment represented US $0.39 billion opportunity over 2019-2021 and estimated to create US $1.34 billion opportunity in 2027 over 2021.

Isothermal Nucleic Acid Amplification Technology (INAAT)

Isothermal Nucleic Acid Amplification Technology (INAAT) segment was valued at US $3.97 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $5.24 billion by 2027. Isothermal Nucleic Acid Amplification Technology (INAAT) segment represented US $0.28 billion opportunity over 2019-2021 and estimated to create US $0.98 billion opportunity in 2027 over 2021.

DNA Sequencing & Next-Generation Sequencing (NGS)

DNA Sequencing & Next-Generation Sequencing (NGS) segment was valued at US $1.58 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $2.08 billion by 2027. DNA Sequencing & Next-Generation Sequencing (NGS) segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.39 billion opportunity in 2027 over 2021.

DNA Microarray

DNA Microarray segment was valued at US $1.49 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $1.97 billion by 2027. DNA Microarray segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.37 billion opportunity in 2027 over 2021.

Other Technologies

Other Technologies segment was valued at US $1.31 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $1.73 billion by 2027. Other Technologies segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.32 billion opportunity in 2027 over 2021.

Disease Type

Introduction

In 2021, Hepatitis segment has the highest revenue of US $16.51 billion and is expected to grow at CAGR of 3.12% by 2027 Hepatitis segment has highest cagr growth of 3.12%.

Hepatitis

Hepatitis segment was valued at US $15.41 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $20.32 billion by 2027. Hepatitis segment represented US $1.10 billion opportunity over 2019-2021 and estimated to create US $3.81 billion opportunity in 2027 over 2021.

Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV) segment was valued at US $9.54 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $12.58 billion by 2027. Human Immunodeficiency Virus (HIV) segment represented US $0.68 billion opportunity over 2019-2021 and estimated to create US $2.36 billion opportunity in 2027 over 2021.

Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)

Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG) segment was valued at US $5.84 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $7.71 billion by 2027. Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG) segment represented US $0.42 billion opportunity over 2019-2021 and estimated to create US $1.45 billion opportunity in 2027 over 2021.

Hospital-Acquired Infections (HAIS)

Hospital-Acquired Infections (HAIS) segment was valued at US $3.74 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $4.94 billion by 2027. Hospital-Acquired Infections (HAIS) segment represented US $0.27 billion opportunity over 2019-2021 and estimated to create US $0.93 billion opportunity in 2027 over 2021.

Human Papillomavirus (HPV)

Human Papillomavirus (HPV) segment was valued at US $2.03 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $2.68 billion by 2027. Human Papillomavirus (HPV) segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.50 billion opportunity in 2027 over 2021.

Tuberculosis (TB)

Tuberculosis (TB) segment was valued at US $1.03 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $1.36 billion by 2027. Tuberculosis (TB) segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.25 billion opportunity in 2027 over 2021.

Influenza

Influenza segment was valued at US $0.88 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $1.16 billion by 2027. Influenza segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.22 billion opportunity in 2027 over 2021.

Other Infectious Diseases

Other Infectious Diseases segment was valued at US $0.17 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $0.23 billion by 2027. Other Infectious Diseases segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.04 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Hospital/Clinical Laboratories segment has the highest revenue of US $16.74 billion and is expected to grow at CAGR of 3.12% by 2027 Hospital/Clinical Laboratories segment has highest cagr growth of 3.12%.

Hospital/Clinical Laboratories

Hospital/Clinical Laboratories segment was valued at US $15.62 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $20.60 billion by 2027. Hospital/Clinical Laboratories segment represented US $1.12 billion opportunity over 2019-2021 and estimated to create US $3.86 billion opportunity in 2027 over 2021.

Reference Laboratories

Reference Laboratories segment was valued at US $9.12 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $12.03 billion by 2027. Reference Laboratories segment represented US $0.65 billion opportunity over 2019-2021 and estimated to create US $2.26 billion opportunity in 2027 over 2021.

Physician Offices

Physician Offices segment was valued at US $7.46 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $9.84 billion by 2027. Physician Offices segment represented US $0.53 billion opportunity over 2019-2021 and estimated to create US $1.85 billion opportunity in 2027 over 2021.

Academic/Research Institutes

Academic/Research Institutes segment was valued at US $5.05 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $6.67 billion by 2027. Academic/Research Institutes segment represented US $0.36 billion opportunity over 2019-2021 and estimated to create US $1.25 billion opportunity in 2027 over 2021.

Other End Users

Other End Users segment was valued at US $1.38 billion in 2019 and is projected to grow at 3.12% CAGR over the forecast period to reach US $1.82 billion by 2027. Other End Users segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.34 billion opportunity in 2027 over 2021.